XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Service Receivable
Accumulated other comprehensive loss
Accumulated Deficit
Balance (in shares) at Dec. 31, 2021   716 41,964        
Balance at Dec. 31, 2021 $ 140,417 $ 1 $ 4 $ 400,503 $ (139) $ (142) $ (259,810)
Increase (Decrease) in Stockholders' Equity              
Stock-based compensation 4,256     4,256      
Issuance of common stock upon exercise of warrants (in shares)     29        
Issuance of common stock upon exercise of warrants 75     75      
Issuance of common stock upon conversion of Convertible Preferred Stock (in shares)   (655) 2,684        
Issuance of common stock upon conversion of Series E Convertible Preferred Stock (1) $ (1)          
Unrealized gain (loss) on securities available-for-sale (253)         (253)  
Release of clinical trial funding commitment 139       139    
Cumulative preferred stock dividend adjustment 414           414
Net loss (38,704)           (38,704)
Balance (in shares) at Dec. 31, 2022   61 44,677        
Balance at Dec. 31, 2022 106,343 $ 0 $ 4 404,834 0 (395) (298,100)
Increase (Decrease) in Stockholders' Equity              
Stock-based compensation 4,509     4,509      
Unrealized gain (loss) on securities available-for-sale 328         328  
Net loss (41,441)           (41,441)
Balance (in shares) at Dec. 31, 2023   61 44,677        
Balance at Dec. 31, 2023 $ 69,739 $ 0 $ 4 $ 409,343 $ 0 $ (67) $ (339,541)